DIN EN ISO 12417-1:2024-08 (E)

Cardiovascular implants and extracorporeal systems - Vascular device-drug combination products - Part 1: General requirements (ISO 12417-1:2024)

Contents

Page

European foreword **4**

Foreword **5**

Introduction **6**

1 Scope **7**

2 Normative references **8**

3 Terms and definitions **8**

4 Intended performance **12**
4.1 General 12
4.2 Classification 12
4.3 Intended clinical location 13

5 Design attributes **13**
5.1 General 13
5.2 Drug-containing part of the VDDCP 13
5.2.1 General 13
5.2.2 Matrix 14
5.2.3 Active pharmaceutical ingredient 14

6 Materials **15**

7 Design evaluation **15**
7.1 General 15
7.2 Pre-clinical evaluation 16
7.2.1 Sampling 16
7.2.2 Conditioning of test samples 16
7.2.3 Pre-clinical in vitro test reports and additional information 17
7.2.4 Pre-clinical in vitro evaluation 17
7.2.5 Preclinical in vivo evaluation 23
7.3 Clinical evaluation 28
7.3.1 Purpose 28
7.3.2 Specific aims 28
7.3.3 Clinical investigation plan 28
7.3.4 Data acquisition 29
7.3.5 Final report 31
7.4 Post-market surveillance 32

8 Manufacturing **32**
8.1 General 32
8.2 Raw material reporting and analysis of the API 32
8.3 Raw material analysis and reporting for excipients 33
8.4 VDDCP batch release testing 33

9 Sterilization **34**
9.1 Products supplied sterile — Testing to support “Sterile” labelling 34
9.2 Products supplied non-sterile 34
9.3 Sterilization residuals 34

10 Packaging **34**
10.1 General 34
10.2 Considerations for VDDCPs 34
10.3 Impact of changes in storage and shipping temperatures on VDDCP 34

11 Information supplied by the manufacturer **35**
11.1 General 35
11.2 Labelling 35
11.2.1 VDDCP label(s) 35
11.2.2 Record label 35
11.3 Instructions for use 36
Annex A (informative) **Description of potential clinical and technical events** **37**
Annex B (informative) **Local information regarding submission issues for VDDCPs** **42**
Bibliography **48**